"Pharmaceutical headline king" several drug companies false invoicing is found Pfizer $500 million investment in place

(2020/06/03) The U.Swants to get rid of its reliance on Chinese medical supplies and policies may change; $7 billion colorectal cancer drug market landscape analysis; Nature sub-issue in-depth review: How to develop anti-aging drugs; Pfizer's $500 million is already in placeOn Monday, BMS announced the official listing of Zeposia, entering the already crowded MS marketMoreover, the company believes that Zeposia has some key advantages over its competitorsOne of them is price advantage, Tina Deignan, head of immunology at BMS USA, told FiercePharma that the company has set Zeposia's annual wholesale purchase price (WAC) at $86,000, which is lower than Novartis's $885,000 equivalent of mayzent, which itself is cheaper than Novartis's old drug GilenyaZeposia is now the lowest-priced oral MS drug on the market in the United StatesThe U.Shas a complex approach to medical supplies from China: in the short term, it can't do without, or even exempt, some tariffs on some products, and, in the medium and long term, try ingress away from dependence on ChinaSince March, the U.S., which is heavily affected by the new crown, has imported heavily medical protection supplies from China and relies on China in its medical supply chainIn the medium- and long-term strategy, the United States has quietly changed its attitude towards China, trying to gradually get rid of its dependence on China in order to achieve "supply chain security"The global industrial chain is likely to change after the new crown outbreakColorectal cancer (CRC) ranked 5th and 3rd, respectively, in China's 2015 list of deaths and incidences of malignant tumorsGlobally, there are about 1.8 million new CRC cases each year, Chinese mainland about 430,000Despite the ongoing introduction of CRC early sieve, nearly 25% of patients were already in the late stages of metastasis (mCRC) at the time of diagnosis, and the five-year survival rate decreased from more than 65% in the early stages to 14.3%Avastin remains dominantAccording to the latest data from Minnet.com, there are 404 brands in China's urban retail pharmacies in 2019, 27 more than in 2018Of these, 242 were chemicals, 27 more than in 2018, and 162 were chinese traditional drugs, the same number as in 2018 In terms of major categories, there are 16 more brands of chemical anti-tumor and immunomodulators than in 2018, with 10 brands growing by more than 100% in 2019 The booming sales of new anti-tumor drugs in DTP pharmacies have pushed the retail pharmacy market to new highs Aging is an unavoidable journey for human beings, and for a long time, people have tried to change the process of aging In fact, the aging process can indeed be changed, and by interfering with different biological systems and signaling pathways, scientists have changed the aging process in a variety of animal models, delaying the weakening of the body function associated with aging and delaying the occurrence of a variety of diseases, including cancer, cardiovascular disease, and neurodegenerative diseases A recent review published in Nature Reviews Drug Discovery provides a deep inventory of the areas of drug discovery for aging-delaying and lists the most promising research anti-aging therapies Although the development of anti-aging drugs also faces a variety of challenges Recently, the State Administration of Taxation Putian City Tax Bureau, the State Administration of Taxation Nanping City Tax Bureau official website respectively hung 8, 66 related to the false opening of VAT invoices, of which many are involved in pharmaceutical enterprises All 8 announcements issued by the tax bureau of Putian City are all related to the pharmaceutical industry, and 35 of the 66 announcements issued by the Nanping Municipal Tax Bureau are related to the pharmaceutical industry Financial compliance is a challenge for pharmaceutical companies Today, Pfizer announced the launch of the Pfizer Breakthrough Growth Initiative, which will set up up to $500 million to invest in biotech companies to help them complete important clinical development projects As we all know, the development of new drugs is a long process, and the cost of time and money is quite expensive Even with cutting-edge technology, it is inevitable that research and development funds will not meet the time If tens of millions of dollars can be invested at this point, it will no doubt be a carbon in the snow to help these small and medium-sized biotech companies complete the sprint How will the $500 million investment be distributed? As the product of the specialized division of labor in the medical diagnosis market, the third-party medical examination industry, driven by the policy of social medical treatment, medical insurance control fee and so on, has entered a rapid growth, the trend of industry transformation has become very obvious, and the chaining and group management has become the trend Especially during the current round of the new crown epidemic, in the unprecedented situation of prevention and control, third-party testing agencies as a force to surface, strong support for the epidemic prevention and control, in the post-epidemic era or will usher in greater development The third-party medical examination industry has a lot of room for growth Drugstore operators are aware that a pharmacy to operate well, customer experience is the top priority Especially when it comes to drugstore promotions, the customer's spending experience Promotion slot, more goods, service, especially from the details to see the store service high and low This so-called service is the value-added service experience that pharmacy training often refers to So how should this great-value experience be divided? The Gold Cup Silver Cup is not as good as the customer's reputation.